Here's what we'll cover Here's what we'll cover Here's what we'll cover People with ovaries are increasingly spending their 20s and 30s moving up the career ladder or achieving financial stability and postponing having kids until later in life
The processes by which GLP-1 receptor agonists exert their effectsenhanced insulin secretion, reduced glucagon secretion, slower gastric emptying, and appetite suppressionare well-characterized and supported by a robust body of preclinical and clinical evidence
Before starting therapy, a good baseline health status matters: labs like fasting glucose or HbA1c to check glucose control, lipid panel, liver/kidney function, and hormone levels to rule out contraindications
General: This medicine is not the same as insulin and you should not use it if: you have type 1 diabetes (your body does not produce any insulin) you develop diabetic ketoacidosis
No human safety data exists for semaglutide, tirzepatide, or other GLP-1 compounds during pregnancy, and animal models show fetal skeletal abnormalities at high doses